CorMedix Awarded European Patent for Neutrolin
Download image CorMedix Logo. (PRNewsFoto/CorMedix Inc.) BRIDGEWATER, N.J., Jan. 10, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and...
View ArticleNEUTROLIN LABEL EXPANSION APPROVED IN GERMANY (CorMedix Inc)
(Source: CorMedix Inc) BRIDGEWATER, N.J., December 3, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
View ArticleCorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At...
CorMedix Logo Facebook Twitter Pinterest × CorMedix Logo BEDMINSTER, N.J., April 23, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and...
View ArticleCorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on...
CorMedix Logo Facebook Twitter Pinterest × CorMedix Logo BEDMINSTER, N.J., April 9, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a global biopharmaceutical company focused on developing and...
View ArticleCorMedix Presents Neutrolin® Post Marketing Surveillance Data at European...
BEDMINSTER, N.J., June 1, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
View ArticleNeutrolin Label Expansion Approved for the European Union (CorMedix Inc)
(Source: CorMedix Inc) BRIDGEWATER, N.J., September 19, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the...
View ArticleCorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution...
CorMedix Logo Facebook Twitter Pinterest × CorMedix Logo BRIDGEWATER, N.J., Dec. 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and...
View ArticleSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class...
WILMINGTON, Del., July 8, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.: Do you, or did you, own shares of CorMedix Inc. (NYSE MKT: CRMD)? Did you purchase your shares between March 12, 2011 and June...
View ArticleCorMedix Receives CE Mark for Neutrolin® Catheter Lock Solution
Drug - Device Shown to Prevent Catheter Related Bloodstream Infections and Maintain Catheter Patency, a Major Health Issue for Patients Requiring Long-term Catheter Use - - Company to Hold Investor...
View ArticlePomerantz Law Firm Announces the Filing of a Class Action Against CorMedix,...
NEW YORK, July 06, 2015 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix, Inc. (“CorMedix” or the “Company”) (NYSE:CRMD) and certain of its...
View ArticleCorMedix Expands Neutrolin® Sales with Middle East Distribution Agreements
Company Establishes Sales and Marketing Oversight Committee for Neutrolin Commercialization Download image CorMedix Logo. (PRNewsFoto/CorMedix Inc.) BRIDGEWATER, N.J., Jan. 13, 2014 /PRNewswire/ --...
View ArticleCorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on...
(Source: CorMedix Inc) CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore BEDMINSTER, N.J., April 9, 2015 -- CorMedix Inc. (NYSE...
View ArticleCRMD INVESTOR ALERT: Investigation of CorMedix, Inc., Announced by Glancy...
Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of CorMedix, Inc. (NYSE: CRMD) (“CorMedix” or “the Company”). The investigation concerns...
View ArticleCorMedix Signs Sales and Marketing Agreement with MKM Co-Pharma, Bolsters...
- Company pursues European marketing plans for lead product; prepares for initiation of U.S. regulatory registration process - BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (NYSE MKT: CRMD), a...
View ArticleCorMedix Presents Neutrolin® Post Marketing Surveillance Data at European...
CorMedix Logo Facebook Twitter Pinterest × CorMedix Logo BEDMINSTER, N.J., June 1, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and...
View ArticleCorMedix Presents Neutrolin® Post Marketing Surveillance Data at European...
(Source: CorMedix Inc) CorMedix Presents Neutrolin® Post Marketing Surveillance Data at European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Conference BEDMINSTER, N.J.,...
View ArticleMediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2...
Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/MediciNova+Receives+Feedback+From+FDA+Regarding+Study+Protocol+for+Phase+2+Trial+of+MN-001+%28tipelukast%29+in+NASH/9897921.html...
View ArticleCorMedix Receives CE Mark for Neutrolin® Catheter Lock Solution (CorMedix Inc)
(Source: CorMedix Inc) Drug - Device Shown to Prevent Catheter Related Bloodstream Infections and Maintain Catheter Patency, a Major Health Issue for Patients Requiring Long-term Catheter Use - -...
View ArticleEQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims...
The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of CorMedix, Inc. (NYSE: CRMD) resulting from allegations...
View Article
